Antibody-drug conjugate

US10117952B2 · kind B2 · utility

Assignee

• DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

• Takeshi Masuda · Tokyo, JP
• Hiroyuki Naito · Tokyo, JP
• Takashi Nakada · Tokyo, JP
• Masao Yoshida · Tokyo, JP
• Shinji Ashida · Tokyo, JP
• Hideki Miyazaki · Tokyo, JP
• Yuji Kasuya · Tokyo, JP
• Koji Morita · Tokyo, JP
• Yuki Abe · Tokyo, JP
• Yusuke Ogitani · Tokyo, JP

Key dates

• Filing date: Oct 10, 2013
• Grant date: Nov 6, 2018
• Expiry date: Oct 10, 2033

Classification

• Technology area (CPC —): General

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.